Core Insights - Akebia Therapeutics reported strong initial sales for Vafseo® (vadadustat) with net product revenues of $12.0 million in Q1 2025, contributing to total net product revenues of $55.8 million for the quarter [1][12] - The company completed a $50 million public offering, enhancing its balance sheet with cash and cash equivalents of $113.4 million as of March 31, 2025 [1][12] - Akebia plans to initiate a Phase 3 clinical trial (VALOR) for vadadustat in late-stage CKD patients not on dialysis, expected to begin in the second half of 2025 [5][31] Vafseo U.S. Commercial Updates - Over 640 prescribers have written prescriptions for Vafseo, averaging nearly 12 prescriptions each, with about one-third being refills [5] - The top five dialysis organizations have placed orders for Vafseo, although mid-sized dialysis organizations are currently driving most of the revenue [5] - Akebia estimates it has at least 12 months of Vafseo inventory on hand in the U.S. without potential incremental tariff payments [5] Financial Results - Total revenues for Q1 2025 were $57.3 million, up from $32.6 million in Q1 2024, driven by Vafseo sales and increased Auryxia sales [12] - Auryxia net product revenues were $43.8 million in Q1 2025, compared to $31.0 million in Q1 2024 [12] - Net income for Q1 2025 was $6.1 million, a significant improvement from a net loss of $18.0 million in Q1 2024 [12] Key Business Highlights - Akebia's Vafseo was recommended for symptomatic anemia in adults undergoing dialysis for CKD by the U.K. National Institute for Health and Care Excellence (NICE) [5] - U.S. Renal Care continues enrollment in the VOICE clinical trial for Vafseo, now at 75% of the planned enrollment of approximately 2,200 patients [5] - The company is advancing its existing programs while pursuing label expansion for Vafseo [12][31]

Core Viewpoint - Akebia Therapeutics (AKBA) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with a consensus outlook suggesting a quarterly loss of $0.03 per share, reflecting a 66.7% improvement from the previous year, and revenues expected to reach $45.21 million, a 38.6% increase from the same quarter last year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, while a miss could lead to a decline in stock value [2]. - The consensus EPS estimate has been revised 30% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +45.46% for Akebia Therapeutics, suggesting a strong likelihood of beating the consensus EPS estimate [11]. - The company currently holds a Zacks Rank of 3, which, when combined with the positive Earnings ESP, indicates a favorable outlook for the upcoming earnings report [11]. Historical Performance - In the last reported quarter, Akebia Therapeutics was expected to post a loss of $0.08 per share but actually reported a loss of $0.10, resulting in a surprise of -25% [12]. - Over the past four quarters, the company has only surpassed consensus EPS estimates once [13]. Industry Comparison - Another player in the Zacks Medical - Drugs industry, Heron Therapeutics (HRTX), is expected to report a loss of $0.01 per share for the same quarter, reflecting a year-over-year change of +50%, with revenues projected at $37.08 million, a 7% increase from the previous year [17]. - Heron Therapeutics has seen a 50% upward revision in its consensus EPS estimate over the last 30 days and holds an Earnings ESP of 100.00%, indicating a strong likelihood of beating the consensus EPS estimate [18].

Akebia to Host Conference Call on May 8, 2025, at 8:00 a.m. EDTCAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking ...

One stock that might be an intriguing choice for investors right now is Akebia Therapeutics, Inc. (AKBA) . This is because this security in the Medical - Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the ...

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025. Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours. Cardiovascular Risk in Patients With DD-CKD Randomi ...

Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [5]. Offering Details - Akebia announced a public offering of 25,000,000 shares of common stock at a price of $2.00 per share, aiming to raise gross proceeds of $50.0 million before expenses [1]. - The underwriters have a 30-day option to purchase up to 3,750,000 additional shares at the public offering price [1]. - The offering is expected to close on March 21, 2025, pending customary closing conditions [1]. Underwriters - Leerink Partners and Piper Sandler & Co. are serving as joint bookrunning managers for the offering, with BTIG, LLC as the lead manager and H.C. Wainwright & Co. as co-manager [2]. Regulatory Compliance - The shares are being offered under a shelf registration statement filed with the SEC on September 3, 2024, which was declared effective on September 12, 2024 [2]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Contact Information - For inquiries regarding the offering, contact details for Leerink Partners and Piper Sandler & Co. are provided [3].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by ki ...

Akebia Therapeutics (AKBA) Q4 2024 Earnings Call March 13, 2025 02:53 PM ET Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate CommunicationsJohn Butler - CEO, President & DirectorNicholas Grund - Senior VP & Chief Commercial OfficerErik Ostrowski - Senior VP, CFO & Chief Business OfficerJulian Harrison - Managing Director Conference Call Participants Allison Bratzel - Senior Research AnalystEd Arce - MD & Senior Healthcare Analyst Operator Good day and welcome to Akebia's Four ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, IR John Butler - CEO Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial & Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Good day, and welcome to Akebia's Fourth Quarter 2024 Financial Results Call. At this time, all participants are in a listen- ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.05 per share when it actually produced a loss of $0.10, delivering a surprise of -100%.Over the last four ...